Anika Therapeutics Inc(ANIK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.27 | Insider Own | 6.28% | Shs Outstand | 13.4M | Perf Week | -0.67% |
| Market Cap | 0.28B | Forward P/E | 28.38 | EPS next Y | 38.68% | Insider Trans | 2.34% | Shs Float | 12.5M | Perf Month | -5.31% |
| Enterprise Value | 0.27B | PEG | 0.24 | EPS next Q | 0.23 | Inst Own | 91.73% | Short Float | 2.75% | Perf Quarter | 41.71% |
| Income | -0.00B | P/S | 2.31 | EPS this Y | 381.82% | Inst Trans | -0.96% | Short Ratio | 3.59 | Perf Half Y | 45.87% |
| Sales | 0.12B | P/B | 2.03 | EPS next 5Y | 118.66% | ROA | -1.68% | Short Interest | 0.35M | Perf YTD | 117.07% |
| Book/sh | 10.26 | P/C | 7.27 | EPS past 3/5Y | 9.4% 14.76% | ROE | -2.19% | 52W High | -8.83% ($22.88) | Perf Year | 141.71% |
| Cash/sh | 2.87 | P/FCF | 498.52 | Sales past 3/5Y | -10.28% -2.86% | ROIC | -2.36% | 52W Low | 147.16% ($8.44) | Perf 3Y | 21% |
| Dividend Est. | - | EV/EBITDA | 521.59 | EPS Y/Y TTM | 93.57% | Gross Margin | 62.16% | Volatility(W/M) | 3.43% 4.54% | Perf 5Y | -47.32% |
| Dividend TTM | - | EV/Sales | 2.2 | Sales Y/Y TTM | -2.5% | Oper. Margin | -4.24% | ATR (14) | 0.89 | Perf 10Y | -54.56% |
| Dividend Ex-Date | - | Quick Ratio | 3.19 | EPS Q/Q | 187.26% | Profit Margin | -3.14% | RSI (14) | 54.24 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.48 | Sales Q/Q | 15.56% | SMA20 | -1.69% ($21.22) | Beta | 0.2 | Target Price | $21 |
| Payout | - | Debt/Eq | 0.18 | Earnings | 2026/7/29 | SMA50 | 10.64% ($18.85) | Rel Volume | 0.73 | Prev Close | $20.99 |
| Employees | 235 | LT Debt/Eq | 0.17 | EPS/Sales Surpr. | 625% 11.62% | SMA200 | 47.2% ($14.17) | Avg Volume(3M) | 0.10M | Price | $20.86 |
| IPO | 1993/5/3 | Option/Short | Yes/Yes | Trades | 1171 | Volume | 70,336 | Change | -0.62% |
Company
ANIK is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🦴 Anika Therapeutics (ANIK) is a U.S. medical company that develops, manufactures, and sells osteoarthritis pain management and orthopedic regenerative solutions based on its proprietary hyaluronic acid (HA) technology. The company operates with two main pillars — joint injection products such as Orthovisc and Monovisc, and a regenerative medicine portfolio — positioning its core HA technology as a key competitive differentiator in the specialty healthcare space.
Over the past 1 year, on the higher side
9% below its 1-year high.
ANIK has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +381.8% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +21.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 91.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
QQQS 0.00%
SQLV 0.00%
SMLV 0.00%
FSEV 0.00%
IWC 0.00%It ranks #4 in the industry
Based on market cap of $279M.
ANIK $279M PER -
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is ANIK?
ANIK belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ANIK?
The market cap of ANIK is approximately $279M, ranking 3,817 within its sector.
What is the 52-week high and low for ANIK?
ANIK has recorded a 52-week high of $22.88 and a low of $8.44.
